ClinicalTrials.gg
Not yet recruitingNCT07950579OASISUpdated Nov 20, 2026

OvariAn Secretome and Integrated HealthSpan

An observational study in Ovarian, Aging and Healthspan Improvement, sponsored by Sheba Medical Center. Not yet recruiting at 1 site in Israel. Open to female participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sheba Medical Center · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
800
Ages
40 Years to 85 Years
Sex
Female
01

Study summary

The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.

Read the detailed description

Background and Purpose:

The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.

Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.

Part 2: Prospective OASIS Cohort

This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:

Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.

Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.

Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.

Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.

02

Conditions studied

  • Ovarian
  • Aging
  • Healthspan Improvement
  • Reproductive Health
  • Women's Health

Keywords

  • Perimenopause
  • Ovarian secretome
  • Ovarian aging
  • Menopause
03

In context

Lead sponsor

Sheba Medical Center is the lead sponsor of 680 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 50-85 years at enrollment (for part 1 retrospective study). or
  • Women aged 40-50 years at enrollment (for part 2 prospective study).
  • Able to understand the study information and provide written .
  • Able and willing to complete the study assessments and follow-up visits.

Part 3 (PRISM substudy) specific criteria:

  • Natural, regular menstruation.
  • Reported menstrual-cycle length of 21-35 days.
  • Willing and able to attend four additional blood-draw and transvaginal ultrasound visits across one menstrual cycle.
  • Signed separate PRISM informed consent.
  • Not using oral , other hormonal contraceptives, menopausal hormone therapy, or another hormonal treatment at PRISM enrollment.

Exclusion criteria

Exclusion Criteria:

  • A former diagnosis of significant cognitive reduction ( score \<24).
  • Former diagnosis of a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or Lewy body dementia.
  • Former diagnosis of psychiatric disease.
  • Underwent chemotherapy or radiation therapy in the past two years.

Part 3 (PRISM substudy) specific criteria:

  • Failure to meet the PRISM inclusion criteria.
  • Unwillingness or inability to sign the PRISM consent.
  • Irregular cycle or reported cycle length outside 21-35 days.
  • Current hormonal , menopausal hormone therapy or other hormonal treatment.
  • Inability or unwillingness to undergo repeated blood draws.
  • Inability or unwillingness to undergo transvaginal ultrasound.
  • A medical condition that, in the investigator's judgment, makes participation unsafe or unsuitable.
  • A medical, technical, or logistical reason that precludes reliable completion of the substudy.
  • Pregnancy, breastfeeding, initiation of hormonal treatment, or a significant medical change during PRISM must be reported to the study team and may lead to discontinuation at the Principal Investigator's discretion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Part 1: Retrospective Biobank Cohort

    500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis.

  • Part 2: Prospective Main Cohort

    300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings.

  • Part 3: PRISM Nested Substudy

    Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes.

06

What researchers measure

Primary outcomes

  1. Reproductive hormone concentrations

    The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples.

    Time frame: Baseline, 12 months, 24 months

  2. Antral Follicle Count (AFC)

    The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound.

    Time frame: Baseline, 12 months, 24 months

  3. Total ovarian volume

    Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries.

    Time frame: Baseline, 12 months, 24 months

  4. Number of participants with abnormal ovarian or adnexal ultrasound findings

    The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded.

    Time frame: Baseline, 12 months, 24 months

  5. Circulating ovarian-associated molecular signature

    Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function.

    Time frame: Baseline, 12 months

  6. Montreal Cognitive Assessment (MoCA) score

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Baseline, 12 months

  7. Apnea-Hypopnea Index (AHI)

    Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep.

    Time frame: Baseline, 12 months

  8. Glycated hemoglobin (HbA1c)

    Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples.

    Time frame: Baseline, 12 months

  9. DXA-derived body composition

    Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg).

    Time frame: Baseline, 12 months

  10. Bone mineral density (BMD)

    Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm².

    Time frame: Baseline, 12 months

  11. Handgrip strength

    Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg).

    Time frame: Baseline, 12 months

  12. Pulse wave velocity (PWV)

    Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s).

    Time frame: Baseline, 12 months

  13. Within-woman changes in reproductive endocrine measures

    Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants.

    Time frame: Up to four sampling time points during the first month of the study

07

Study locations

1 site
  • Sheba Medical Center
    Ramat Gan, Tel Aviv 5262000, Israel
    • Abigail Goshen · Contact972542270050
    • Abigail Goshen, PhD · Principal investigator
    • Lauren Petrick, PhD · Principal investigator
    • Yaron Rabinovici, Dr · Sub investigator
08

References and documents

Publications

  • Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020 Dec;114(6):1151-1157. doi: 10.1016/j.fertnstert.2020.09.134. PubMed 33280722 ↗
  • Moolhuijsen LME, Visser JA. Anti-Mullerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020 Nov 1;105(11):3361-73. doi: 10.1210/clinem/dgaa513. PubMed 32770239 ↗
  • Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, Johnston J, Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009 May 26;72(21):1850-7. doi: 10.1212/WNL.0b013e3181a71193. PubMed 19470968 ↗
  • Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012 Apr;19(4):387-95. doi: 10.1097/gme.0b013e31824d8f40. PubMed 22343510 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
May 1, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950579
Collaborators
Nuttall Women's Health (NWH)
Responsible party
Dr. Abigail Goshen (Director, Healthy longevity research institute, Sheba Medical Center) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Nov 1, 2029 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Abigail Goshen, PhD
Contact
Abigail.Goshen@sheba.health.gov.il
972542270050
Abigail Goshen, PhD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion